BACKGROUND:Vitamin D has immunomodulatory effects that might aid clearance of mycobacterial infection. We aimed to assess whether vitamin D supplementation would reduce time to sputum culture conversion in patients with active tuberculosis. METHODS: We did this randomised, double-blind, placebo-controlled, superiority trial at 13 sites in India. Treatment-naive patients who were sputum-smear positive, HIV negative, and had pulmonary tuberculosis were randomly assigned (1:1), with centrally labelled, serially numbered bottles, to receive standard active tuberculosis treatment with either supplemental high-dose oral vitamin D3 (four doses of 2·5 mg at weeks 0, 2, 4, and 6) or placebo. Neither the patients nor the clinical and laboratory investigators and personnel were aware of treatment assignment. The primary efficacy outcome was time to sputum culture conversion. Analysis was by modified intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00366470. FINDINGS:Between Jan 20, 2010, and Aug 23, 2011, we randomly assigned 247 participants to thevitamin D group (n=121) or the placebogroup (n=126), of whom 211 participants (n=101 and n=110, respectively) were included in the primary efficacy analysis. Median time to culture conversion in the vitamin D group was 43·0 days (95% CI 33·3-52·8) versus 42·0 days (33·9-50·1) in the placebo group (log-rank p=0·95). Three (2%) patients died in the vitamin D group and one (1%) patient died in the placebo group; no death was considered attributable to the study intervention. No patients had hypercalcaemia. INTERPRETATION: Our findings show that vitamin D supplementation did not reduce time to sputum culture conversion. Further studies should investigate the role of vitamin D in prevention or reactivation of tuberculosis infection. FUNDING: Dalhousie University and Infectious Diseases Training and Research Centre.
RCT Entities:
BACKGROUND:Vitamin D has immunomodulatory effects that might aid clearance of mycobacterial infection. We aimed to assess whether vitamin D supplementation would reduce time to sputum culture conversion in patients with active tuberculosis. METHODS: We did this randomised, double-blind, placebo-controlled, superiority trial at 13 sites in India. Treatment-naive patients who were sputum-smear positive, HIV negative, and had pulmonary tuberculosis were randomly assigned (1:1), with centrally labelled, serially numbered bottles, to receive standard active tuberculosis treatment with either supplemental high-dose oral vitamin D3 (four doses of 2·5 mg at weeks 0, 2, 4, and 6) or placebo. Neither the patients nor the clinical and laboratory investigators and personnel were aware of treatment assignment. The primary efficacy outcome was time to sputum culture conversion. Analysis was by modified intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00366470. FINDINGS: Between Jan 20, 2010, and Aug 23, 2011, we randomly assigned 247 participants to the vitamin D group (n=121) or the placebo group (n=126), of whom 211 participants (n=101 and n=110, respectively) were included in the primary efficacy analysis. Median time to culture conversion in the vitamin D group was 43·0 days (95% CI 33·3-52·8) versus 42·0 days (33·9-50·1) in the placebo group (log-rank p=0·95). Three (2%) patients died in the vitamin D group and one (1%) patient died in the placebo group; no death was considered attributable to the study intervention. No patients had hypercalcaemia. INTERPRETATION: Our findings show that vitamin D supplementation did not reduce time to sputum culture conversion. Further studies should investigate the role of vitamin D in prevention or reactivation of tuberculosis infection. FUNDING: Dalhousie University and Infectious Diseases Training and Research Centre.
Authors: Vishal Sharma; Harshal S Mandavdhare; Amit Kumar; Ravi Sharma; Naresh Sachdeva; Kaushal K Prasad; Surinder S Rana Journal: Ther Adv Infect Dis Date: 2017-05-25
Authors: Giuseppe Saggese; Francesco Vierucci; Flavia Prodam; Fabio Cardinale; Irene Cetin; Elena Chiappini; Gian Luigi De' Angelis; Maddalena Massari; Emanuele Miraglia Del Giudice; Michele Miraglia Del Giudice; Diego Peroni; Luigi Terracciano; Rino Agostiniani; Domenico Careddu; Daniele Giovanni Ghiglioni; Gianni Bona; Giuseppe Di Mauro; Giovanni Corsello Journal: Ital J Pediatr Date: 2018-05-08 Impact factor: 2.638
Authors: Nestan Tukvadze; Ekaterina Sanikidze; Maia Kipiani; Gautam Hebbar; Kirk A Easley; Neeta Shenvi; Russell R Kempker; Jennifer K Frediani; Veriko Mirtskhulava; Jessica A Alvarez; Nino Lomtadze; Lamara Vashakidze; Li Hao; Carlos Del Rio; Vin Tangpricha; Henry M Blumberg; Thomas R Ziegler Journal: Am J Clin Nutr Date: 2015-09-23 Impact factor: 7.045
Authors: Davaasambuu Ganmaa; Baatar Munkhzul; Wafaie Fawzi; Donna Spiegelman; Walter C Willett; Purev Bayasgalan; Erkhembayar Baasansuren; Burneebaatar Buyankhishig; Sereeter Oyun-Erdene; David A Jolliffe; Theodoros Xenakis; Sabri Bromage; Barry R Bloom; Adrian R Martineau Journal: Am J Respir Crit Care Med Date: 2017-09-01 Impact factor: 21.405
Authors: Bintou A Ahidjo; Mariama C Maiga; Elizabeth A Ihms; Mamoudou Maiga; Alvaro A Ordonez; Laurene S Cheung; Sarah Beck; Bruno B Andrade; Sanjay Jain; William R Bishai Journal: JCI Insight Date: 2016-09-08